Trillium Therapeutics (NASDAQ: TRIL) and Tetralogic Pharmaceuticals (OTCMKTS:TLOG) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends and profitability.
Risk & Volatility
Trillium Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. Comparatively, Tetralogic Pharmaceuticals has a beta of 2.82, meaning that its share price is 182% more volatile than the S&P 500.
47.5% of Trillium Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Tetralogic Pharmaceuticals shares are owned by institutional investors. 15.4% of Tetralogic Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This table compares Trillium Therapeutics and Tetralogic Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Trillium Therapeutics and Tetralogic Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Trillium Therapeutics||N/A||N/A||-$23.96 million||($3.79)||-2.74|
|Tetralogic Pharmaceuticals||N/A||N/A||-$49.72 million||($1.65)||-0.02|
Trillium Therapeutics is trading at a lower price-to-earnings ratio than Tetralogic Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent ratings and price targets for Trillium Therapeutics and Tetralogic Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Trillium Therapeutics presently has a consensus price target of $12.50, suggesting a potential upside of 20.19%. Given Trillium Therapeutics’ higher probable upside, equities research analysts plainly believe Trillium Therapeutics is more favorable than Tetralogic Pharmaceuticals.
Tetralogic Pharmaceuticals beats Trillium Therapeutics on 5 of the 9 factors compared between the two stocks.
Trillium Therapeutics Company Profile
Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companys lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.
Tetralogic Pharmaceuticals Company Profile
TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company’s histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.
What are top analysts saying about Trillium Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Trillium Therapeutics Inc. and related companies.